INS and Hypoglycemia: Wang et al. (2022) explored the quantitative relationship between dapagliflozin and loss of weight in T1DM patients and found that to achieve the plateau period in the loss of weight, 5 mg/day dapagliflozin was required for at least 41.6 weeks. Li et al. (2022) found that dapagliflozin treatment significantly decreased HbA1c, insulin dosage, and body weight without increasing the risk of hypoglycemia in T1DM.